🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCompounding & FormulationFDA June 2026 enforcement update — compounding pharmacies Page 17

FDA June 2026 enforcement update — compounding pharmacies

RegAffairsDC Mon, Feb 26, 2024 at 4:00 PM 366 replies 55,812 viewsPage 17 of 20
RegAffairsDC
Member
678
3,456
May 2024
Washington, DC
Jun 29, 2025 at 5:22 AM#81

OP back with an update, since a thread like this is useless without one.

Update — I was wrong in the opening post, specifically about the direction. Correcting it here rather than editing it away.

29 4amy_econ_NJ, bbq_ray_KC, oliver_london and 26 others
Reply Quote Save Share Report
rick_sfbay
Member
289
1,234
Jan 2025
San Francisco, CA
Jul 6, 2025 at 4:54 PM#82

Old thread, but it comes up first when you search for this, so it is worth updating. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

28 3NicoleRaleigh, james_edin, FranDenver and 25 others
Reply Quote Save Share Report
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Jul 14, 2025 at 4:22 AM#83

Adding the clinical framing, because it changes how the question reads. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.

Last edited: Jul 14, 2025 at 8:22 AM
27 2FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 24 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.ReproEndo
Senior Member
1,890
8,901
Jan 2024
Scottsdale, AZ
Jul 21, 2025 at 3:45 PM#84
PeptideChemSF said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

Second this.

26 1GraceAZ_72, carl_compliance, DanielChem_CHI and 23 others
Reply Quote Save Share Report
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
Jul 29, 2025 at 3:04 AM#85
PeptideChemSF said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

There is a second half to this that has not been said yet. Worth answering the question that was asked rather than the one behind it. The narrow version usually has an answer; the broad version usually does not, and answering the broad one is how a thread stops being useful.

25 0wanda_boise, NurseAsh_DET, BenResearch_OR and 22 others
Reply Quote Save Share Report

Similar Threads

503A vs 503B compounding — regulatory framework explained4 replies
Compounded semaglutide stability: accelerated degradation study results6 replies
Lyophilized vs liquid peptides — stability and bioavailability comparison18 replies
Bacteriostatic water sourcing and sterility considerations8 replies
State-by-state compounding pharmacy regulations — 2026 map8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register